Lower Doses of XXXX in Combination With @entity7855 Might be @entity120 .

@entity1 @entity12584 @entity120 @entity8577 @entity7855 @entity1031
BACKGROUND: Endothelin-receptor-antagonist, @entity12584 , has been found to improve the functional capacity and cardiopulmonary hemodynamics in @entity120 ( @entity120 ). Clinical trials have shown the preferable dosage of 125 mg, twice daily, regarding both efficacy and safety. OBJECTIVES: The purpose of this study was to investigate the effects of lower doses of @entity12584 (62.5 mg, twice daily) in combination with @entity7855 on exercise capacity and clinical events, in 41 @entity1 with @entity8577 or @entity120 ( @entity120 ). @entity1 AND METHODS: We assigned 41 @entity1 with @entity120 (non-reactive idiopathic or non-operable chronic @entity1031 ) to receive 62.5 mg of @entity12584 twice daily as combination therapy and evaluated the New York heart association (NYHA) functional class, 6-minutes-walk-distance (6MWD), time to clinical worsening, echocardiographic indexes and clinical events, for an average of 18.5    9.5 months. RESULTS: No adverse drug reaction was observed during the follow-up. Clinical worsening occurred in six (14%) @entity1 , at least one year after treatment, two of the cases failed to respond to 125 mg, twice daily and died. Eight (19%) remained in FC I_II, but didn't reach the goal of 380 meters for 6MWD. All other @entity1 reached the treatment goals according to the latest European society of cardiology (ESC) guidelines. CONCLUSIONS: We observed acceptable results regarding both efficacy and safety with 62.5 mg of @entity12584 , twice daily in this group of @entity1 . Further clinical trials investigating @entity120 with lower dosages of @entity12584 may be warranted.
